Search research articles
Contact Us
Filters
Showing results (221-230 of 242) with videos related to
Page
of 25
Sort By:
The Lancet. Oncology
|
October 9, 2019
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Cancer Science
|
July 5, 2018
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations
Haruyasu Murakami, Hiroshi Nokihara, Hidetoshi Hayashi, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic <i>EGFR</i>-Mutated NSCLC: RELAY Japanese Subset
Kazuto Nishio, Takashi Seto, Makoto Nishio, et al.
Cancer Treatment and Research Communications
|
July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer
Emiliano Calvo, Alexander Spira, María de Miguel, et al.
JTO Clinical and Research Reports
|
July 22, 2024
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
Benjamin J Solomon, Ibiayi Dagogo-Jack, Se-Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
Cancer Science
|
November 13, 2020
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR)
Kazuko Sakai, Masahiro Tsuboi, Hirotsugu Kenmotsu, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 242) with videos related to
Sort By:
Page
of 25
The Lancet. Oncology
|
October 9, 2019
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Cancer Science
|
July 5, 2018
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations
Haruyasu Murakami, Hiroshi Nokihara, Hidetoshi Hayashi, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic <i>EGFR</i>-Mutated NSCLC: RELAY Japanese Subset
Kazuto Nishio, Takashi Seto, Makoto Nishio, et al.
Cancer Treatment and Research Communications
|
July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer
Emiliano Calvo, Alexander Spira, María de Miguel, et al.
JTO Clinical and Research Reports
|
July 22, 2024
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
Benjamin J Solomon, Ibiayi Dagogo-Jack, Se-Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
Cancer Science
|
November 13, 2020
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR)
Kazuko Sakai, Masahiro Tsuboi, Hirotsugu Kenmotsu, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Page
of 25